Aslan Pharmaceuticals Pte. Ltd., of Singapore, reported results from a phase I trial of ASLAN002 (BMS-777607), a small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint, showing that the drug was safe and well tolerated at all doses tested in 39 solid tumor patients, who received treatment for a minimum of 28 days as both once-daily and twice-daily dose regimens.